Clinical Observation of Vinorelbine Combined with Capecitabine for Advanced Breast Cancer

Objective To investigate the efficacy and toxicity of Vinorelbine(NVB) combined with Capecitabine in the treatment of advanced breast cancer.Methods Vinorelbine 25 mg/m2 rapid infusion on days 1,8,and oral Capecitabine 1 000 mg/m2 twice daily for 14 days were administered every three weeks.All patients received at least two cycles of the treatment.Results Twenty-eight patients were enrolled and were treated previously.All patients were included in the efficacy and adverse events analysis.There were 1 case complete response(3.6%),12 partial responses(42.8%),giving an overall response rate of 46.4%.The major toxicity included myelotoxicity and hand-foot syndrome and were generally mild.Conclusion Vinorelbine combined with Capcitabine demonstrates clinical activity and an acceptable safety profile in patients with advanced breast cancer.Further investigation is warranted.